

1. Record Nr.	UNINA9910506403503321
Titolo	Microbiome in human health and disease // Pallaval Veera Bramhachari, editor
Pubbl/distr/stampa	Gateway East, Singapore : , : Springer, , [2021] ©2021
ISBN	981-16-3156-5
Descrizione fisica	1 online resource (306 pages)
Disciplina	616.9041
Soggetti	Human body - Microbiology Microbiota Llibres electrònics
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Intro -- Foreword -- Preface -- Acknowledgements -- About the Book -- Contents -- Editor and Contributors -- Abbreviations -- Part I: Introduction to Microbiomes -- 1: Microbiomes and Its Significance with the Current Applications in Human Health and Disease: Goals and Challenges of Microbi... -- 1.1 Introduction -- 1.2 The Complexity of the Microbiomes -- 1.3 Co-Evolution of Microbiomes with Humans -- 1.4 Microbiome Dysbiosis -- 1.5 Significance of Microbiome Research. -- 1.6 The Way Forward -- References -- Part II: Microbiome for Human Health: From Basic Science to Immune-Microbiome Interactions -- 2: Modulation of Systemic Immune Responses Through Genital, Skin, and oral Microbiota: Unveiling the Fundamentals of Human Mic... -- 2.1 Introduction -- 2.2 Genital Microbiome -- 2.2.1 Modulation of the Genital System -- 2.3 Skin Microbiome -- 2.3.1 Skin Architecture -- 2.3.2 Association of Microorganisms and Skin Diseases -- 2.3.3 Topography of Skin -- 2.3.4 Skin Modulation -- 2.4 Oral Microbiome -- 2.4.1 Ecology of the Oral Microbiome -- 2.4.2 Association of Microbiota and Oral Diseases -- 2.4.2.1 Caries -- 2.4.2.2 Periodontal Diseases -- 2.4.2.3 Oral Tumor and Recurrent Aphthous Stomatitis -- 2.4.2.4 Association with Systemic Diseases -- 2.4.3 Modulation of the Oral Microbiome -- 2.5 Conclusion -- References -- 3: A Systematic Review on Crosstalk Between Microbiome and Immune System -- 3.1

Introduction -- 3.2 Role of Microbiota in Hematopoiesis -- 3.3 Microbiome and Innate Immune Responses -- 3.4 Cutaneous Immunity and Microbiome Interactions -- 3.5 Microbiome-Mucosal Cell Surface Interactions -- 3.6 Microbiome and Adaptive Immunity -- 3.7 Microbiome and Cell-Mediated Immunity -- 3.8 Microbiome and Humoral Immunity -- 3.9 Microbiome and Immune System Dysbiosis -- 3.10 Concluding Remarks -- References.

4: Diversity and Dynamics of the Gut Microbiome and Immune Cells -- 4.1 Introduction to Gut Microbiota -- 4.2 Interactions Between Gut Microbiota and Immune System -- 4.3 Innate Immunity and Gut Microbiota -- 4.4 Adaptive Immunity and Gut Microbiota. -- 4.4.1 T cells -- 4.4.2 B Cells -- 4.5 Role of Gut Microbiota in Disease Development -- 4.6 Type 1 Diabetes -- 4.7 Rheumatoid Arthritis -- 4.8 Inflammatory Bowel Disease (IBD) -- 4.9 Celiac Disease (CD) -- 4.10 Systemic Lupus Erythematosus (SLE) -- 4.11 Cancer -- 4.12 Conclusion and Future Perspectives -- References -- 5: Overview on Human Gut Microbiome and its Role in Immunomodulation -- 5.1 Human Gut Microbiome -- 5.2 Gut Microbes During Pregnancy and Early Infancy -- 5.3 Shaping of Maternal Gut Microbes with Proper Diet during Pregnancy -- 5.4 Gut Microbes: Onset of Cancer -- 5.5 Immunomodulation -- 5.5.1 Immunomodulation by Microbial Components -- 5.5.2 Immunomodulation by Metabolites -- 5.6 Tumor Immunotherapy -- 5.7 Conclusion -- References -- 6: Cancer Microbiome and Immunotherapy: Understanding the Complex Responses Between Microbes, Immunity, and Cancer -- 6.1 Introduction -- 6.2 Microbiome for Well-Being -- 6.3 The Microbiome and Immunity -- 6.4 Infection and Malignant Growth -- 6.5 The Inclination of Malignancy Patients to Obtain Infection Disease(s) -- 6.6 The Activity of the Microbiota in Malignant Growth Vulnerability -- 6.6.1 Pancreatic Cancer -- 6.6.2 Breast Cancer -- 6.6.3 Colorectal Cancer -- 6.6.4 Gastric Malignancy -- 6.7 Nitty Gritty of the Microbiome in Malignant Growth Treatment -- 6.7.1 Chemotherapy -- 6.7.2 Checkpoint Inhibitors -- 6.7.3 Microbial Metabolites -- 6.7.4 Cytokine Therapy -- 6.7.5 Adoptive Cell Treatment -- 6.8 Concluding Remarks -- References -- 7: Dynamics of Respiratory Microbiome Profiles Contributes to Imbalance and Lung Dysbiosis in the Respiratory Tract. 7.1 Overview of Respiratory Microbiome -- 7.2 Human Microbiome Project and Molecular Characterization of Respiratory Microbiome -- 7.3 Determinants of Respiratory Microbiome -- 7.4 Reactive Nitrogen Species (RNS) in Respiratory Tract Inflammation -- 7.5 Dynamics of Respiratory Microbiome in Health and Disease -- 7.5.1 Smoking -- 7.5.2 Antibiotics -- 7.6 Chronic Respiratory Disorders -- 7.6.1 COPD -- 7.6.2 Asthma -- 7.6.3 Cystic Fibrosis -- 7.6.4 Idiopathic Pulmonary Fibrosis -- 7.6.5 Lung Transplantation -- 7.7 Conclusions and Future Perspectives -- References -- 8: Understanding the Interplay Between the Host Immune-Microbiome Interactions: A State of the Art Review -- 8.1 Introduction -- 8.2 Microbiome-Immune System Interaction -- 8.3 Experimental Tools for Analyzing the Microbiota Immune System Interactions -- 8.4 Interaction of Microbiota-Immune Homeostasis -- 8.5 Innate Immunity with Epithelial Barrier Defense -- 8.6 Innate Immune Cell's Barrier -- 8.7 Influence of Microbiota on the Immune System -- 8.7.1 Outside-In Signals of Microbiota -- 8.7.2 Inside-Out Signals of Microbiota -- 8.8 Microbiota Protection Against Autoimmune Diseases -- 8.9 Microbiota in Modulating Immune Responses in Cancer -- 8.10 Role of Metabolites in Microbiota and Immune System -- 8.11 Advancements to Identify Mechanisms of Immune Interaction -- 8.12 Conclusion and Future Perspectives -- References -- Part III:

Microbiome for Human Health: Clinical Applications -- 9: Intestinal Microbiome-Macromolecule Signaling That Mediates Inflammation and Immune System Interaction -- 9.1 Introduction -- 9.2 Interactions of Microbiota and Immune System -- 9.3 Mediators of Inflammation -- 9.4 Mitochondria and Gut Microbiome Signaling -- 9.5 Cytokines Influenced by Gut Microbiota -- 9.6 Conclusion -- References -- 10: Microbiome Diagnostics and Interventions in Health and Disease. 10.1 Introduction -- 10.2 Need for Human Microbiome-Based Diagnostics -- 10.3 Challenges in Design, Analysis, and Interpretation -- 10.4 An Informed Approach to Next-Gen Sequencing-Based Microbiome Diagnostic Design and Evaluation -- 10.5 The Healthy Gut Microbiome -- 10.6 Microbiome Therapeutics -- 10.6.1 Prebiotics Support Probiotics -- 10.6.2 Probiotics in Food and as Supplements -- 10.6.3 Postbiotics -- 10.6.4 Fecal Microbiota Transplantation (FMT) -- 10.6.5 Research-Driven Probiotics: The Future -- 10.7 The Role of Microbiome Diagnostics and Therapeutics in a Few Disease Scenarios -- 10.7.1 Atherosclerosis -- 10.7.2 Hypertension -- 10.7.3 Obesity -- 10.7.4 Nonalcoholic Fatty Liver Disease -- 10.7.5 Type 2 Diabetes -- 10.7.6 Inflammatory Bowel Disease (IBD) -- 10.7.7 Irritable Bowel Syndrome (IBS) -- 10.7.8 Fecal Microbial Transplantation in Clostridium difficile Infections -- 10.7.9 Chronic Kidney Disease -- 10.7.10 Cancer -- 10.7.11 Mental Disorders -- 10.7.12 Rheumatoid Arthritis -- 10.8 Conclusion -- References -- 11: Microbiome Therapeutics: Emerging Concepts and Challenges -- 11.1 Introduction -- 11.1.1 Colon Rectal Cancer (CRC) Therapy -- 11.1.2 Gut Microbiome and Chimeric Antigen Receptor (CAR) T-Cell Therapy. -- 11.1.3 Irritable Bowel Syndrome (IBS) Therapy -- 11.1.3.1 Prebiotics -- 11.1.3.2 Probiotics -- 11.1.3.3 Dietary Therapy -- 11.1.3.4 FMT -- 11.1.4 Inflammatory Bowel Diseases (IBDs) Therapy -- 11.1.4.1 Gut Microbiota Mediated Immunomodulation Therapy -- 11.1.4.2 Precision Edited Gut Microbiota Mediated Therapy -- 11.1.4.3 Probiotics Mediated Therapy -- 11.1.4.4 Engineered Probiotics Mediated Therapy -- 11.1.4.5 Microbial Metabolites Mediated Therapy -- 11.1.4.6 Intestinal Stem Cells-Gut Microbiota Mediated Therapy -- 11.1.5 Microbiome-Based CDI Therapy -- 11.1.5.1 Probiotics -- 11.1.5.2 FMT. 11.1.6 Microbiome Therapeutics for Food Allergy (FA) -- 11.1.7 Microbiome Therapy for Autoimmune Diseases -- 11.1.7.1 Type 1 Diabetes (T1D) -- 11.1.7.2 Multiple Sclerosis -- 11.1.7.3 Rheumatoid Arthritis -- 11.1.7.4 Systemic Lupus Erythematosus (SLE) -- 11.1.8 Cardiovascular Disease (CVD) -- 11.1.9 Microbiome-Based Therapy for Non-Communicable Diseases (NCD) -- 11.2 Conclusion -- References -- 12: Recent Advancements in Microbiome-Immune Homeostasis and their Involvement in Cancer Immunotherapy -- 12.1 Introduction -- 12.2 Microbiome -- 12.2.1 Esophageal Microbiota -- 12.3 Healthy and the Unhealthy Microbiome -- 12.3.1 Healthy Microbiome -- 12.3.2 Unhealthy Microbiome -- 12.4 Techniques and Tools for Microbiome Analysis -- 12.5 Microbiome Therapies -- 12.6 Microbiome in Mice and Humans -- 12.7 Role of the Microbiome in Healthy Individuals -- 12.8 Microbiota Effects on Immune System Development -- 12.9 Microbiome Role in Epithelial Barrier -- 12.10 Microbiome as a Marker -- 12.11 Microbiome Affecting Cancer -- 12.12 Microbiome in Cancer Immunotherapy -- 12.12.1 CD47 Blockade with Bifidobacteria -- 12.12.2 PD-L1 Blockade Assisted with Bifidobacterium -- 12.12.3 CTLA-4 Blockade Assisted with Bacteroidales -- 12.12.4 Short-Chain Fatty Acids in Treatment for Cancer -- 12.13 Future Perspectives -- 12.14 Conclusion -- References -- 13: Insight into the Animal Models for Microbiome Studies -- 13.1 Introduction -- 13.2 Mouse as the Animal Model for Human Microbiota Studies -- 13.3 Germ-Free and

Antibiotics Treatment Models -- 13.3.1 GF Mice as Experimental Models -- 13.4 Other Models -- 13.4.1 Zebrafish (*Danio rerio*) -- 13.4.2 Fruit Fly (*Drosophila*) -- 13.4.3 Dogs (*Canis familiaris*) -- 13.4.4 Rabbits (*Oryctolagus cuniculus*) -- 13.4.5 Pigs (*Sus scrofa domesticus*) -- 13.5 Conclusions -- References.  
14: Bioinformatics Algorithms and Software for Predicting Microbiomes

---